Skip to main content

Pharming receives Orphan Drug Designation from the European Commission for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)

Operational updates

Pharming Group N.V. today announces that the European Commission has granted orphan drug designation for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA).

Read more

Pharming Group announces the nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors

Operational updates

Pharming Group N.V. announces the nomination of Barbara Yanni and Mark Pykett to its Board of Supervisory Directors. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming’s Board of Supervisory Directors.

Read more

Filters

  • Cookies: This website uses cookies Check the cookies page for more information Accept Decline